Yabao Pharmaceutical's Valuation Upgrade Signals Potential Growth Amid Challenges

Yabao Pharmaceutical Group Co., Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. The company’s valuation grade has been revised from fair to very attractive, reflecting a notable shift in its financial metrics. Key indicators reveal a P/E ratio of 23, alongside a price-to-book value of 1.65. The enterprise value to EBITDA stands at 12.44, while the EV to EBIT is recorded at 18.11. Additionally, Yabao boasts a dividend yield of 8.35%, which is appealing in the current market landscape. The return on capital employed (ROCE) is at 9.99%, and the return on equity (ROE) is noted at 7.02%. Despite some challenges, including a decline in net sales and pre-tax profit in recent periods, the company has shown resilience with a profit increase of 18.6% over the past year. The PEG ratio is reported at 1.1, indicating a balanced valuation relative to growth expectations. For those interested in further insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.